anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to application of paeonol in preparation of cosmetic for eliminating macula and whitening skin or in preparation of medicament for whitening skin or curing pigment deposition ailment. The cosmetic and medicament are both external use. The mass concentration of said paeonol is 0.01-5 %, optimization scheme is 5-10%. The paeonol and ground substance carrier are mixed to form tincture, spirit, cataplasm, ointment, cream, emulsion, oil agent, face mask, gel, film coating agent, aerosol and solution agent to which other component such as light screening agent and/or antioxidant and/or component for eliminating macula and whitening skin except paeonol can be added. The mechanism of paeonol directly restraining tyrosine enzyme activity, melanin generation and transport is various. The application of paeonol in cosmetic or medicament has unambiguous effect on skin whitening and curing pigment deposition ailment.
Crown rot caused by Fusarium pseudograminearum is a devastating wheat disease worldwide. In addition to yield losses, the fungi causing Fusarium crown rot (FCR) also deteriorate the quality and safety of food because of the production of mycotoxins. Planting resistant cultivars is an effective way to control FCR. However, most wheat cultivars are susceptible to FCR. Therefore, development of new sources and detection of loci for FCR resistance are necessary. In the present study, a resistant mutant, fcrZ22, was identified from an ethyl methane sulfonate (EMS)-mutagenized population of the cultivar Zhoumai 22, and then fcrZ22 was crossed with the wild type to produce an F2 population. Genetic analysis of the F2 population was carried out by the mixed inheritance model of major genes plus polygenes, and 20 resistant and 20 susceptible plants were selected to assemble mixed pools. Combining 660K SNP arrays, the resistance loci were detected by bulked segregant analysis. The resistance to FCR caused by F. pseudograminearum in the F2 population was in accordance with the "mixed model with two major genes of additive-epistasis effect + additive-dominant polygenes," and the heritability of the major gene was 0.92. Twenty-one loci were detected, which were located on 10 chromosomes, namely, 1B (1), 1D (1), 2A (3), 1B (1), 3A (3), 3B (3), 4A (2), 5A (2), 7A (3), and 7B (2). Among the 21 loci, eight were new loci for FCR resistance. This is the first report of detecting loci for FCR resistance from a mutant. The results of the present study provided excellent germplasm resources for breeding wheat cultivars with FCR resistance and laid the foundation for fine mapping of FCR resistance loci.
The appts. to separate blood into blood components has a bypass channel (18) to give a path round the filter (11) between the collection vessel (1) and the primary vessel (2).  A system (19,20) opens and closes the bypass (18) and opens and closes the collection channel (9). Also claimed is a blood separation operation where whole blood is collected in a vessel, to be passed through an initial path to a primary vessel where, by centrifugal forces, the whole blood is separated into a layer of erythrocytes and a mixed layer of blood plasma and thrombocytes.  The mixed layer is passed to a satellite vessel.  An additive is delivered from a supply point to the primary vessel to suspend the erythrocytes.  The suspension is returned to the collection vessel, through a filter which separates the erythrocytes.  The satellite vessel is separated, and the cutting point is sealed or clamped.
Parkinson's disease (PD) is a neurodegenerative disorder affecting 2-3% of those aged over 65, characterized by motor symptoms like slow movement, tremors, and muscle rigidity, along with non-motor symptoms such as anxiety and dementia. Lewy bodies, clumps of misfolded proteins, contribute to neuron loss in PD. Mutations in the GBA1 gene are considered the primary genetic risk factor of PD. GBA1 mutations result in decreased activity of the lysosomal enzyme glucocerebrosidase (GCase) resulting in α-synuclein accumulation. We know that α-synuclein aggregation, lysosomal dysfunction, and endoplasmic reticulum disturbance are recognized factors to PD susceptibility; however, the molecular mechanisms connecting GBA1 gene mutations to increased PD risk remain partly unknown. Thus, in this narrative review conducted according to a systematic review method, we aimed to present the main contributions arising from the molecular impact of the GBA1 gene to the pathogenesis of PD providing new insights into potential impacts for advances in the clinical care of people with PD, a neurological disorder that has contributed to the substantial increase in the global burden of disease accentuated by the aging population. In summary, this narrative review highlights the multifaceted impact of GBA1 mutations in PD, exploring their role in clinical manifestations, genetic predispositions, and molecular mechanisms. The review emphasizes the importance of GBA1 mutations in both motor and non-motor symptoms of PD, suggesting broader therapeutic and management strategies. It also discusses the potential of CRISPR/Cas9 technology in advancing PD treatment and the need for future research to integrate these diverse aspects for improved diagnostics and therapies.
Guaifenesin (glyceryl guaiacolate) has the chemical name 3-(2-methoxyphenoxy)-1,2-propanediol. Its molecular formula is C10H14O4 with a molecular weight of 198.21. It is a white or slightly gray crystalline substance with a slightly bitter aromatic taste. One gram dissolves in 20 mL water at 25°C; it is freely soluble in ethanol. Guaifenesin is readily absorbed from the GI tract and is rapidly metabolized and excreted in the urine. Guaifenesin has a plasma half-life of one hour. The major urinary metabolite is β-(2-methoxyphenoxy) lactic acid.

Guaifenesin is an expectorant available for oral administration as:

Tablets — each containing 200 mg guaifenesin, USP.

Other ingredients: crospovidone, D&C red #30 aluminum lake, magnesium stearate, microcrystalline cellulose, polysaccharides, pregelatinized starch, silicon dioxide, sodium starch glycolate, and stearic acid.
On Study Visit Day 8, subjects will receive a 1 g oral dose of resveratrol followed 2 hours later by a single oral dose of midazolam (2 mg). Blood and urine will be collected to measure midazolam and its metabolites, and resveratrol and its metabolites.
The invention relates to genetic engineering, in particular to a fusion gene of a single-chain antibody of a target human epidermal growth factor receptor HER-2 under the guidance of a soluble promoting molecular chaperone SUMO and a superantigen SAg and a preparation method thereof. The gene has a base sequence in a sequence table SEQ ID No. 1 and can encode an amino acid sequence in a sequence table SEQ ID No. 2. When a prokaryotic expression vector is used for expressing the fusion gene in the invention, the guiding of the SUMO molecular chaperone can enhance the correct folding of the downstream single-chain antibody and superantigen fusion protein, thereby obtaining higher amount of soluble fusion protein. The fusion protein takes an anti-HER-2 single-chain antibody as a targeting molecule and SAg protein as an effector molecule, and can generate specific cell inhibition effect on HER-2 receptor over-expressed tumor cells.
Non ST-segment elevated acute coronary syndrome(NSTE-ACS) is increasing rapidly, and is more frequent than ST-segment elevated acute coronary syndrome (STE-ACS) now. NSTE-ACS patients sent to early PCI procedure is large and increasing rapidly in China.Quite a few trials have focused on high loading dose statin before PCI to improve cardiovascular outcomes in ACS. In Asian, high loading dose statin therapy showed different outcome. Rosuvastatin (RSV) is one of the most potent statins.Nowadays, quite a few experts think ACS patients undergoing PCI not only need loading dose statin, but also post PCI intensive statin treatment is rather important. Chinese consensus and western guidelines recommend intensive statin treatment in these patients. However, Chinese consensus referred to the western study as there's no relevant intensive statin treatment peri-PCI study in China until now.

Thus this study is designed to explore the efficacy of intensive statin treatment peri-PCI (early loading dose-RSV 40 mg or 20mg before PCI and subsequent 20mg post PCI) in periprocedural myocardial injury and 30 days MACE reduction in Chinese NSTE-ACS patients and explore efficacy of 30-day RSV 20 mg post-PCI treatment in lipid profile, inflammatory factors compared with baseline.
A remotely activated piezoelectric pump for delivery of biological agents to the intervertebral disc and spine in order to achieve spinal fusion. A spinal pump is implanted on the vertebrae of a patient and a spinal cage is inserted in between two adjacent vertebrae after removal of the vertebrae disc. A piezoelectric motor drives the pump and pushes osteogenetic agent through the spinal cage and into a sponge disposed within the cage. The pump is charged by an external removable induction belt worn by the patient. Delivery duration and delivery frequency may be changed before implantation of the spine pump according to the specific needs of the patient. The current device employs a mathematical model that enables the regulation as well as attenuation of the bone fusion process by extending and generalizing the model to enhance and optimize the delivery of osteogenetic agent in a regulated manner.
PURPOSE:To obtain polyolefin resin treated (extender) pigment, having strong affinity for oil agent, providing smooth cosmetic with good feeling, by coating the surface of pigment with a carboxyl group-containing polyolefin resin. CONSTITUTION:A carboxyl group-containing polyolefin resin is dissolved in a petroleum type hydrocarbon, blended with pigment (e.g. titanium oxide, etc.) and dried to coat the surface of the pigment with the resin or a solution having dissolved the carboxyl group-containing polyolefin resin is dissolved or emulsified into water dispersion of the pigment, an aqueous solution of a soluble salt (e.g. aluminum sulfate, etc.) of Al, etc. is dripped to the solution or emulsion. The resulting material is dehydrated, dried and the resin is orientated and adsorbed on the surface of the pigment to give polyolefin resin-treated (extender) pigment.
PROBLEM TO BE SOLVED: To realize the operation simulation of high reality by providing three- dimensional reconstitution from a tomographic picture, executing an operation using a surgical operation input device on a display device and indicating a close degree to a concerned area. SOLUTION: Sliced inspection pictures are inputted to an arithmetic unit 3 from an inspection picture input device 5 at every prescribed interval and a three-dimensional reconstitution picture processor 6 executes a three- dimensional reconstitution processing. An overlap processor 7 generates the synthesized picture of a three-dimensional reconstitution picture and an operation instrument picture by an operation instrument picture generation device 4 and display it on the display device 8. At that time, the concerned area to which attention is to be paid at the time of executing the operation is previously set in the three-dimensional reconstitution picture. A warning signal generation device 10 generates a warning signal when a distance between the tip of the operation instrument picture and the concerned area becomes smaller than a distance which is previously set.  The warning signal gives force feed back to the surgery operation input device 1 and it is converted into at least one of tactility, pressure and feeling to an operator and it is indicated.
The following adverse reactions have been identified during postapproval use of irbesartan and hydrochlorothiazide tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to irbesartan and hydrochlorothiazide tablets.

The following have been very rarely reported with irbesartan and hydrochlorothiazide monotherapies: urticaria, jaundice, hepatitis, thrombocytopenia, and impaired renal function including renal failure. 

The following have been reported with irbesartan monotherapy: tinnitus, hyperkalemia, angioedema (involving swelling of the face, lips, pharynx, and/or tongue), anaphylactic reaction including anaphylactic shock, increased CPK, and anemia.

The following have been reported with hydrochlorothiazide monotherapy: acute angle-closure glaucoma, acute myopia and choroidal effusion. Non-melanoma Skin Cancer 

Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
BACKGROUND: Children with Developmental Coordination Disorder (DCD) can experience sensory differences. There has been limited exploration of these differences and their impact on children with DCD.
AIMS: i) To explore the presence and impact of sensory differences in children with DCD compared to children without DCD; ii) To examine whether sensory differences are related to motor ability, attention deficit hyperactivity disorder (ADHD), or autistic traits.
METHOD: Parents of children (8-12 years) with (n = 23) and without (n = 33) DCD used standardised questionnaires to report on their children's sensory differences, autistic traits, and ADHD traits. Motor abilities were assessed through the Movement Assessment Battery for Children-2. Data were explored both categorically (between-groups) and dimensionally.
RESULTS: Children with DCD had significantly higher levels of sensory differences than children without DCD. Sensory differences also had a significantly greater impact on daily activities for children with DCD. Higher levels of ADHD and autistic traits, but not motor ability, were significant independent predictors of higher levels of sensory difference.
CONCLUSION: Children with DCD experience high levels of sensory differences, which impact on their daily lives. These sensory differences may be a marker for additional neurodivergence in children with DCD. Practitioners should consider the sensory needs of children with DCD.
WHAT THIS PAPER ADDS: This paper provides insight into the sensory features of children with DCD and the impact that sensory differences can have on daily living. Using parent-report, we found that children with DCD had increased sensory differences relative to children without DCD. These included increased hyperresponsiveness, increased hyporesponsiveness, and increased sensory interests, repetitions, and seeking behaviours (SIRS). We also found that sensory differences had a greater impact on daily living for children with DCD compared to children without DCD. Across the whole sample, autistic traits predicted hyperresponsivity and hyporesponsivity patterns; whereas traits of hyperactivity and impulsivity predicted SIRS. Motor abilities did not uniquely predict sensory differences, suggesting that other traits of neurodivergence may contribute to the sensory differences in DCD. Taken together, these findings highlight the necessity of considering sensory needs when supporting children with DCD. They also suggest that if sensory differences are identified in children with DCD, it may be due to the presence of co-occurring neurodivergent traits or conditions.
Post-traumatic stress disorder (PTSD) is a highly prevalent and disabling disorder that affects about 7.7 million adults in the United States. PTSD can develop after someone experiences a particularly distressing event that may involve the threat of or actual physical harm. Common symptoms of PTSD include avoidance of situations or cues that may act as reminders of the event, reoccurring flashbacks of the event, loss of interest in previously enjoyed activities, and numbing of emotions. Additionally, PTSD is often associated with far-reaching and devastating interpersonal relationship problems that can maintain or aggravate other PTSD symptoms. These interpersonal problems can also interfere with successful treatment delivery, so addressing such problems is important for improving treatment compliance, effectiveness, and long-term success. Cognitive behavioral therapy (CBT) is a type of psychotherapy that teaches ways to modify thoughts and behaviors that contribute to PTSD. CBT that is adapted for couples in which one partner has PTSD may be the most effective means of decreasing individual PTSD symptoms and improving the couple's relationship. This study will evaluate the effectiveness of cognitive behavioral couples therapy (CBCT) for PTSD in reducing symptoms of PSTD and in improving relationship functioning for couples in which one partner has PTSD.

Participation in this study will last 8 months. All participants will undergo baseline assessments that will include an interview about exposure to traumatic events, PTSD symptoms, mental health problems, and substance use; self-report questionnaires about mood, social and leisure activities, and relationships; and a brief video-recorded communication session as a couple. Eligible participants will then be assigned randomly to receive immediate CBCT for PTSD or delayed CBCT for PTSD. Participants in the delayed treatment group will receive active treatment after a 3-month waitlist period. CBCT for PTSD will include fifteen 75-minute couples therapy sessions, occurring twice weekly for 3 weeks and weekly for the remaining 9 weeks of treatment. Sessions will follow manual-based couples therapy and will aim to both decrease individual PTSD symptoms and enhance dyadic functioning. After each session, participants will also complete out-of-session practice assignments that will include completing worksheets and practicing skills taught in therapy sessions.

Participants receiving immediate CBCT for PTSD will undergo subsequent assessments at mid-treatment, end of treatment, and 3 months after the end of treatment. Participants receiving delayed treatment will undergo assessments 1 and 3 months into the wait-list period and at the end of treatment. Assessments will include questions about PTSD and mental health symptoms, alcohol and substance use, intimate relationship functioning, and family and social activities. Participants will repeat the communication session after the end of treatment for the group receiving immediate therapy and at the end of the wait-list period for the delayed treatment group.
Symptoms: Exceeding the recommended dose in patients with normal renal function or administering the recommended dose to patients with impaired renal function (common in elderly patients) may lead to increased serum levels and toxic reactions. Methemoglobinemia generally follows a massive, acute overdose. Methylene blue, 1 to 2 mg/kg/dose given i.v. as a 1% solution as needed, should cause prompt reduction of the methemoglobinemia and disappearance of the cyanosis which is an aid in diagnosis. Oxidative Heinz body hemolytic anemia also may occur, and "bite cells" (degmacytes) may be present in a chronic overdosage situation. Red blood cell G-6-PD deficiency may predispose to hemolysis; however, hemolysis may occur at normal doses in patients with G-6-PD Mediterranean. Renal toxicity and occasional failure and hepatic impairment may also occur. 

Treatment: Treatment is symptomatic and supportive.
A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level. AMV564 will be tested as a 14-Day CIV regimen (14-Day Continuous Intravenous Infusion Regimen).
The invention belongs to the technical field of traditional Chinese medicine preparation method, and provides a preparation method of a traditional Chinese medicine used for treating gastritis caused by insufficiency of spleen-yang. According to prior arts, gastritis caused by insufficiency of spleen-yang is commonly treated by using omeprazole, which causes adverse reactions. The technical scheme of the invention is that: traditional Chinese medicines of ginseng, human milk, common jujube, common yam rhizome, wheat, different leaves pseudostellaria root tuber, balck-bone silky fowl, wild cabbage, dried longan pulp, largehead atractylodes rhizome, radix paeoniae alba, American ginseng, ligusticum, lotus seed, pilose asiabell root, sharpleaf galangal fruit, mongolian milkvetch root, Siberian solomonseal rhizome, nonglutinous rice, edible bird nest, dried ginger, bayberry, garden radish seed, carica papaya, roof iris rhizome, carrot, buckwheat, medicated leaven, cydonia oblonga mill, cerealose, honey, and licorice are soaked in water, and are decocted by using a mild fire; the obtained solution is filtered, a slag is removed, and the obtained medicine liquid is the traditional Chinese medicine used for treating gastritis caused by insufficiency of spleen-yang. The method is advantaged in that: the preparation method is simple; toxic and side-effects of the traditional Chinese medicine liquid are low; a treatment course is short; and a recovery rate is high. According to the invention, a good effect can be obtained with the cooperation of monarch and minister medicines. A traditional Chinese medicine preparation is adopted, such that adverse reactions, allergic reactions and toxic reactions caused by western medicines are avoided.
The invention discloses a Chinese herbal medicine for treating headache due to deficiency of blood. The Chinese herbal medicine is prepared from the following medicines in parts by weight: 20-30 parts of American ginseng, 25-30 parts of Chinese angelica, 25-30 parts of prepared rehmannia rhizome, 35-40 parts of sealwort, 35-40 parts of tall gastrodia tuber, 25-30 parts of dahurian angelica root, 25-30 parts of Szechuan lovage rhizome, 15-20 parts of fineleaf schizonepeta herb, 25-30 parts of premna microphylla turez, 25-30 parts of divaricate saposhnikovia root and 15-25 parts of buerger pipewort flower. The Chinese herbal medicine is prepared by carrying out the following steps: adding 1500 parts of water; decocting with soft fire for 20-30 minutes; collecting supernatant and mixing uniformly; bottling; sterilizing for later use. The Chinese herbal medicine composition for treating headache due to deficiency of blood can be used for effectively treating headache due to deficiency of blood. As proved by years of clinical experience, the Chinese herbal medicine is safe and free from side effects. The Chinese herbal medicine is very remarkable in effect, convenient to take and low in treatment cost, and has the effect of treating both symptoms and root causes.